Immune-mediated necrotizing myopathy (IMNM) is a rare form of idiopathic immune myopathy (IIM) that requires immunotherapies, including immunosuppressive medications, if severe. There is a paucity of data regarding outcomes of patients with immune-mediated polymyositis who continue immunosuppressive medications during the COVID-19 pandemic. This is the first reported case of COVID-19 in a patient with IMNM. Despite being on two immunotherapies, having risk factors, and having radiographic abnormalities on chest X-ray, the patient had an unremarkable COVID-19 course. He was discharged from the emergency department with a 7-day course of azithromycin and quickly resumed his immunotherapies, but he experienced a flare in his myositis. The 14-week follow-up computed tomography (CT) was negative for residual pneumonitis or fibrosis. More data are needed regarding management and prognosis of patients with connective tissue diseases who become infected with SARS-CoV-2.
【초록키워드】 COVID-19, Risk factors, COVID-19 pandemic, fibrosis, outcome, immune, Computed tomography, management, Patient, chest X-ray, Follow-up, Immune-mediated, paucity of data, connective tissue disease, immunotherapies, immunosuppressive medications, Immunosuppressive medication, Course, reported, the patient, discharged, prognosis of patient, infected with SARS-CoV-2, radiographic abnormality, 【제목키워드】 COVID-19, Myopathy, Bilateral, Man,